The HNMT enzyme, which clears intracellular histamine, depends on SAMe, a molecule produced through the methylation pathway
Retrieved from Fornes, A., Huff, J., Pritchard, R
Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said
Catalent declined to comment on whether it was preparing for layoffs in the case the deal is blocked
Evidence signal Provider-reviewed bundle 8 source-backed citations are connected to this page
Obesity Drug Development Landscape 73 Obesity drugs organized by drug classes (e.g., GLP-1, GLP-1+GIP, Amylin, etc.) and development phases (Phase 1, Phase 2, Phase 3, Approved)